Purevax RCPCh FeLV Lyophilisate and Solvent for Suspension for Injection

Cats
Common
(1 to 10 animals / 100 animals
treated):
Transient apathy, anorexia, and
hyperthermia
(observed during safety and
field studies).
Injection site reactions (slight pain at
palpation, itching or limited oedema)
(observed during safety and field studies)
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Hypersensitivity reaction
(observed in field
studies)
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Emesis
; transient hyperthermia and lethargy,
sometimes associated with lameness
(based
on post-marketing experience)
lasting usually for 1 or 2 days
disappearing within 1 or 2 weeks at most
may require appropriate symptomatic treatment

Revised: March 2023
AN: 00559/2022
mostly within 24 to 48 hours
observed 1 to 3 weeks following booster vaccination in adult cats
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for respective contact details.